Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elisrasib - D3 Bio

Next Previous
Drug Profile

Elisrasib - D3 Bio

Alternative Names: D3S-001

Latest Information Update: 27 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator D3 Bio
  • Class 2 ring heterocyclic compounds; Acetonitriles; Alcohols; Alkenes; Aniline compounds; Antineoplastics; Azabicyclo compounds; Benzoates; Bridged bicyclo compounds; Carbamates; Cyclohexanols; Cyclohexenes; Esters; Fluorinated hydrocarbons; Fluorobenzenes; Heterocyclic bicyclo compounds; Heterocyclic compounds with 4 or more rings; Ketones; Methyl ethers; Piperazines; Pyrans; Pyrimidines; Pyrrolidines; Small molecules; Toluenes; Xylenes
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Colorectal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 02 Jun 2026 Efficacy, adverse events, pharmacokinetics and pharmacodynamics data from a phase I/II trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 01 Jun 2026 Updated efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
  • 22 Apr 2026 Efficacy, pharmacodynamics, pharmacokinetics and adverse events data from a phase I/II trial in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research, 2026 (AACR-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top